The Global Health Body Issues Warning Over Severe Shortage of Weight-Loss Medications
Fewer than 10% of individuals who could benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it issues its initial guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable availability to GLP-1 medication.
According to forecasts, more than two billion will be obese by 2030 unless action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to universal availability to the jabs that can help people shift considerable body mass, notes the organization.
Weight-Loss Drug Scarcity
Despite the current most favorable outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, according to the WHO.
The guideline encourages governments and firms to expand access, by strategies like patent sharing.
The intellectual property rights on semaglutide – the core component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs mimick a biological compound to slow digestion, curb appetite and enhance feelings of fullness so users eat less.
People typically start to lose weight after several weeks of commencing the weekly injections.
Studies suggests people may see weight return within a year of discontinuing the drug, because their normal hunger return.
To be above a healthy weight increases your risk for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
